SCHEMBL3341845

SCHEMBL3341845

CN(C(=O)c1ccc(-c2ccccc2)cc1)N(C)c1nc(-c2ccc([N+](=O)[O-])cc2)cs1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.60
RAB9A P51151 5/20 0.60
ALDH1A1 P00352 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
KMT2A Q03164 3/20 0.55
MAPK1 P28482 2/20 0.55
MEN1 O00255 2/20 0.55
LMNA P02545 2/20 0.55
GAA P10253 1/20 0.55
GRM1 Q13255 6/20 0.53
NPC1 O15118 3/20 0.49
ALOX15 P16050 1/20 0.49
POLB P06746 1/20 0.48
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
ALOX12 P18054 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4732495 0.85 MAPT (0.56) MAPTRAB9AALDH1A1SMN1; SMN2KMT2A
SCHEMBL3337530 0.80 RAB9A (0.57) MAPTRAB9AALDH1A1KMT2AMEN1
SCHEMBL7472306 0.76 MAPT (1.00) MAPTRAB9AALDH1A1SMN1; SMN2KMT2A
SCHEMBL17107155 0.75 GRM1 (0.87) MAPTRAB9ASMN1; SMN2KMT2AMAPK1
SCHEMBL3341227 0.74 MAPT (0.51) MAPTRAB9AALDH1A1SMN1; SMN2KMT2A
SCHEMBL1008125 0.74 MAPT (0.67) MAPTRAB9AALDH1A1SMN1; SMN2KMT2A
SCHEMBL4780726 0.74 MAPT (0.53) MAPTRAB9AALDH1A1SMN1; SMN2KMT2A
SCHEMBL8361062 0.73 MAPT (0.65) MAPTRAB9AALDH1A1SMN1; SMN2KMT2A
SCHEMBL17131999 0.73 GRM1 (0.81) MAPTRAB9ASMN1; SMN2KMT2AMAPK1
SCHEMBL4798176 0.73 GRM1 (0.55) MAPTRAB9AALDH1A1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA MAPT 2/4885RAB9A 2591/4885ALDH1A1 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.